Related Experiment Video

Updated: Aug 19, 2026

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

Peroxisome proliferator-activated receptor alpha and hypertensive heart disease

Maria J Goikoetxea1, Javier Beaumont, Javier Díez

  • 1Area of Cardiovascular Pathophysiology, Centre for Applied Medical Research, University Clinic, School of Medicine, University of Navarra, Pamplona, Spain.

Drugs
|March 16, 2005
PubMed

Insights

Peroxisome proliferator-activated receptor alpha (PPARalpha) is crucial for heart cell energy. Deactivated PPARalpha may worsen heart failure, suggesting activators could offer cardioprotection.

Area of Science:

  • Cardiovascular Biology
  • Metabolic Regulation
  • Molecular Endocrinology

Background:

  • Peroxisome proliferator-activated receptor alpha (PPARalpha) is a nuclear receptor in cardiomyocytes.
  • PPARalpha regulates genes vital for myocardial lipid and energy metabolism.
  • Its activity impacts cardiomyocyte lipid homeostasis and ATP production.

Purpose of the Study:

  • To investigate the role of PPARalpha deactivation in cardiac hypertrophy and heart failure.
  • To explore the potential cardioprotective effects of PPARalpha activators.

Main Methods:

  • Analysis of existing animal and human data on PPARalpha activity in cardiac conditions.
  • Review of pharmacological agents targeting PPARalpha.

Main Results:

  • Evidence suggests PPARalpha deactivation contributes to phenotypic changes in pressure-overloaded hearts.
  • Compromised PPARalpha activity may link compensated hypertrophy to heart failure in hypertensive disease.

Conclusions:

  • Restoring PPARalpha activity via available activators (e.g., fibric acid derivatives, statins) warrants investigation.
  • These compounds may offer cardioprotection beyond lipid-lowering effects in hypertrophied and failing hearts.

More Related Videos

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats10:28

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Published on: December 5, 2017

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...